downsize_vibes
Active member
the FDA regulatory activity on compounded peptides is moving faster than most people who aren't following it closely realize - the sequence of moves since late 2025 has been narrowing the window for compounded versions of brand-name drugs specifically, and the practical impact on availability is real and ongoing. the community is a faster source of updates on what's actually accessible than any official announcement cycle